Changing the game one dose at a time

A handheld dosing device to make personalizing and connecting medicines effortless

Individualized

Flexible and tailored dosing – delivering dosing at the right time and titration according to patient needs and disease management. Personalized user identification ensures that only the right person uses the device.

Simple

An intuitive and easy-to-use handheld device that dispenses micro-pellets – making life much easier for patient groups with trouble swallowing conventional tablets and capsules.

Connected

Born digital, the device can connect to a wide range of health technologies. A companion app can support adherence and self-monitoring. Remote dose control and diagnostic devices create great opportunities to improve treatment outcomes.

“Increasing knowledge into personalized medicine has demonstrated the need for individual dosing. Drug dosage forms are urgently needed enabling an individual therapy, especially for oral drug delivery.”

Wening K et al. Int J Pharm. 2011 Feb 14;404(1-2):1-9.

OnDosis aims to be a game changer

The demand for reinvented dosing is at an all-time high

Personalized medicine will drive the need for individualised dosing

Digital connectivity has the potential to revolutionize healthcare

Children & the elderly require tailored doses and simpler ways to take medicines

Society shares an increased concern over abuse of prescription drugs

Providers look for better ways of delivering and measuring outcomes

Pharmaceutical innovation has accelerated, but the way of dosing medicines to patients has stayed the same. At OnDosis, we believe it is time that dosing of medicines catches up to the scientific advances of modern medicine. And we’re about to make it happen.

OnDosis is focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. We are currently exploring the use of the OnDosis smart device for individualised dosing in important cases such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.

Newsroom

Press release
October 2017 | Download

Article in Göteborgs-Posten
December 2017 | Read more

Article in Life Time
April 2018 | Read more

Article in Ny Teknik
May 2018 | Read more

Want to know more?

Martin Olovsson
CEO & co-founder of OnDosis. Martin is a senior business leader with 25 years of experience in high profile general management and global leadership roles at AstraZeneca. He has been responsible for several launches, significant P&L’s and global franchise strategies as well as device and e-health development programs.

He is now spearheading OnDosis, driven by the opportunity to bring an exciting innovation to the market.

Mail LinkedIn